Neglected Tropical Disease Treatment Market (2025 - 2033)

Neglected Tropical Disease Treatment Market Summary

The global neglected tropical disease treatment market size was estimated at USD 3.96 billion in 2024 and is projected to reach USD 6.04 billion by 2033, growing at a CAGR of 4.78% from 2025 to 2033. The demand for these treatments is driven by the increasing prevalence of neglected tropical diseases in low-income regions, as well as advancements in drug development and global health initiatives aimed at eradicating these diseases.

Various global health initiatives, advancements in drug development, and innovative delivery methods greatly influence the neglected tropical disease treatment market. A major factor driving growth in this market is increasing attention from governments and international health organizations. The World Health Organization (WHO) has effectively coordinated mass drug administration (MDA) programs for diseases like lymphatic filariasis, trachoma, and soil-transmitted helminths. According to the World Health Organization (WHO), in April 2025, the United States withdrew funding from NTD programs, impacting 47 campaigns over 19 years. This withdrawal affected 143 million people and disrupted mass treatment efforts. The funding reductions also impeded research, threatening progress toward eliminating diseases such as lymphatic filariasis, onchocerciasis, and schistosomiasis. These efforts, along with commitments from organizations like the Global Fund to Fight AIDS, Tuberculosis, and Malaria, are essential in reducing the disease burden in resource-limited settings, especially in sub-Saharan Africa and Southeast Asia.

Another significant driver of the NTD treatment market is the focus on advancing drug formulations to address the unique challenges posed by neglected diseases. New treatments are being developed to improve efficacy, reduce treatment duration, and enhance patient compliance. According to Reuters, in May 2025, Novartis committed to continuing the production of malaria and leprosy medicines despite potential funding cuts. The company produces 28 million malaria treatment courses annually, mostly sold at not-for-profit prices. Despite challenges from reduced international aid, Novartis remains dedicated to supplying essential medicines, investing nearly USD 490 million in research for malaria and neglected tropical diseases. Despite potential challenges in global health funding, such as cuts in official development assistance, these companies continue to play a vital role in ensuring that treatments remain available to those who need them the most.

In terms of technological advancements, the integration of novel drug delivery systems and digital health innovations is improving both the effectiveness and accessibility of treatments. Nanotechnology, for example, is being explored as a way to enhance the bioavailability of drugs, allowing for more effective treatments even in resource-constrained environments. In July 2025, Swiss medical authorities approved Coartem Baby (also known as Riamet Baby), the first malaria treatment specifically designed for newborns and infants weighing under 11 pounds. Developed by Medicines for Malaria Venture in collaboration with Novartis, the drug addresses a critical treatment gap. It is expected to be rolled out in several African nations, where malaria remains a leading cause of death among children under five. These innovations are not only improving therapeutic outcomes but also making treatments more accessible to populations that previously lacked reliable healthcare options. Additionally, mobile health technologies are helping to bridge the gap in healthcare access, enabling better disease monitoring and management in remote areas, further enhancing the market's potential.

These developments reflect a growing momentum in the NTD treatment space, driven by collaborative efforts between governments, pharmaceutical companies, and global health organizations. With new drug formulations, the commitment of major pharmaceutical players, and technological innovations, the market is poised to continue evolving in its mission to control and ultimately eradicate neglected tropical diseases.

Pipeline Analysis

Recent advancements in the clinical development of treatments for neglected tropical diseases have shown promising results. A notable example is the novel formulation of nifurtimox for Chagas disease, which has demonstrated improved pharmacokinetics and reduced side effects compared to traditional formulations. This development is significant, as Chagas disease remains a major public health challenge in Latin America. Additionally, a study published in February 2025 highlighted the potential of ivermectin to reduce mosquito bites and curb malaria transmission. Conducted in Kwale, Kenya, the trial involved over 20,000 children aged 5 to 15 and found a 26% decrease in new malaria infections among those who received monthly doses of ivermectin over three months, even alongside the use of insecticide-treated bed nets. The drug demonstrated a strong safety profile with only mild, temporary side effects. These findings suggest that ivermectin could become a vital new malaria-fighting tool, especially in regions with rising malaria cases and mosquito resistance to existing controls.

According to an update from April 2023, the R21/Matrix-M™ malaria vaccine developed by the University of Oxford has received regulatory approval in Ghana and Nigeria. Ghana's approval marked the world's first for the vaccine, which is intended for children aged 5 to 36 months, the group most at risk of malaria-related deaths. With a 77% efficacy rate demonstrated in clinical trials, this vaccine shows promise for substantially reducing malaria-related deaths worldwide. The vaccine's approval is part of over 30 years of malaria vaccine research at Oxford. It has begun being administered to children in sub-Saharan Africa, aiming to make a significant impact in the fight against malaria, which claimed 608,000 lives in 2022, with three-quarters of those victims being children under five. The vaccine's development was led by the Jenner Institute at Oxford University, with Dr. Mehreen Datoo playing a key role in its clinical development. These developments underscore the ongoing efforts to address neglected tropical diseases through innovative treatments and strategic investments, aiming to improve health outcomes in affected regions.

Opportunity Analysis

The neglected tropical disease treatment market presents a clear opportunity driven by the high burden of disease and the persistent gap in available therapies. Diseases such as schistosomiasis, lymphatic filariasis, and leishmaniasis continue to affect hundreds of millions globally, yet treatment options remain limited. For example, schistosomiasis alone affects over 240 million people, with praziquantel being the primary treatment. According to the WHO, in November 2024, over 657 million people in 39 countries remain at risk of lymphatic filariasis and require preventive chemotherapy. Since the launch of the Global Programme to Eliminate Lymphatic Filariasis in 2000, 9.7 billion treatments have been delivered, significantly reducing transmission. However, due to its limited efficacy against certain species and the growing risk of resistance, the market is poised for novel therapies. Current research, including the development of a single-dose treatment for schistosomiasis, has demonstrated promising results in clinical trials, increasing the likelihood of market adoption. This demand for new, more effective treatments aligns with the priorities outlined in the WHO’s 2021-2030 roadmap, which emphasizes the urgent need for expanded therapeutic options for NTDs.

In addition to drug development, advancements in combination therapies and multi-disease diagnostic platforms, particularly for co-occurring diseases like lymphatic filariasis and onchocerciasis in endemic regions. This market is further supported by strong financial backing, such as, in December 2023, the Gates foundation, in partnership with global health leaders, announced a significant expansion of the RLMF to USD 500 million. This initiative aims to eliminate lymphatic filariasis and onchocerciasis (river blindness) across 39 countries in Africa and Yemen. The expanded funding is expected to ensure that over 350 million people no longer require treatment for these diseases by 2030.. The increasing recognition of NTDs as a significant public health issue in areas with limited healthcare infrastructure is also driving demand for affordable, scalable treatment solutions. Pharmaceutical companies have a strategic opportunity to capitalize on both the unmet needs in these regions and emerging treatment innovations.

Market Concentration & Characteristics

The neglected tropical disease (NTD) treatment market is moderately concentrated, with dominant players such as GlaxoSmithKline, Merck & Co., and Novartis, who lead with established treatments like albendazole and ivermectin. These companies leverage strong brand recognition, extensive clinical data, and robust distribution networks. However, the increasing presence of emerging competitors and generic manufacturers is contributing to price competition and driving innovation. The market is experiencing rapid growth in regions like Africa and Southeast Asia, fueled by the high burden of NTDs and improvements in healthcare infrastructure. The entry of new players and the expansion of combination therapies are reshaping the market dynamics, stimulating continued growth.

The NTD treatment market is marked by a high degree of innovation, encouraged by ongoing research and the development of new therapies. Fixed-dose combination therapies and multi-disease diagnostic platforms are notable innovations, improving treatment outcomes and patient adherence. These advancements allow for more efficient management of co-occurring diseases in endemic regions. Additionally, combination therapies designed to address multiple diseases simultaneously offer significant improvements in therapeutic effectiveness. Such innovations are enhancing the clinical utility of NTD treatments, providing more comprehensive solutions for both healthcare providers and patients.

Entering the NTD treatment market presents several significant challenges, particularly the high costs associated with research and development, along with stringent regulatory requirements. New treatments must undergo extensive clinical trials and multiple submissions to regulatory bodies such as the FDA and EMA, which can delay market entry. The market is further complicated by the dominance of established players who benefit from robust clinical data and distribution networks, creating barriers for new entrants. The competitive landscape also includes the increasing availability of generics, making it difficult for newcomers to capture market share. These factors make it challenging to introduce novel products in the NTD treatment space.

Regulatory bodies such as the FDA and EMA play a key role in shaping the NTD treatment market by ensuring that new medications meet high safety and efficacy standards. The approval process is difficult, with many treatments requiring extensive clinical data before being granted approval. For example, the approval of new NTD treatments often involves several rounds of submission and re-evaluation. While these regulatory standards ensure patient safety, they also increase the time and cost associated with market entry. Once approved, however, these treatments often benefit from established reimbursement pathways, facilitating broader access to healthcare and market penetration. According to Lampit, in July 2023, the FDA approved nifurtimox for the treatment of Chagas disease in pediatric patients aged birth to less than 18 years and weighing at least 2.5 kg, highlighting a significant advancement in the treatment options available for this neglected tropical disease.

The NTD treatment market faces competition from alternative therapies, including generic versions of existing treatments like albendazole and ivermectin. Emerging therapies targeting specific co-endemic diseases may offer different mechanisms of action, potentially influencing prescribing patterns. Moreover, the growing availability of generics introduces cost-effective options, further pressuring the market. Despite these substitutes, NTD treatments continue to maintain a strong position in the market due to their multifaceted benefits, including their proven efficacy in controlling parasitic infections, reducing the burden of co-endemic diseases, and improving overall public health outcomes.

The NTD treatment market is witnessing significant geographical expansion, particularly in emerging markets where the burden of NTDs remains high. In 2024, with Asia Pacific experiencing the growth due to increasing NTD prevalence, better healthcare infrastructure, and greater awareness of available treatments. However, challenges such as high drug costs and limited access to healthcare in rural or low-income areas may impede market penetration. To address these issues, pharmaceutical companies are adopting strategies like tiered pricing and forming partnerships with local healthcare providers, aiming to enhance the accessibility and affordability of NTD treatments in these regions.

Disease Insights

Dengue by disease in the neglected tropical disease treatment market has the largest revenue share of 11.37% of in 2024, driven by factors such as the rising incidence of dengue in tropical and subtropical regions, particularly in Asia Pacific. Takeda's tetravalent dengue vaccine, Qdenga (TAK-003), has been approved in over 40 countries, including the European Union, United Kingdom, Brazil, Argentina, Indonesia, and Thailand. The vaccine has demonstrated efficacy in preventing symptomatic dengue and hospitalizations across all four serotypes, regardless of prior exposure. In May 2024, the World Health Organization (WHO) prequalified Qdenga, recommending its use in children aged 6-16 years in settings with high dengue transmission intensity. Additionally, heightened awareness and increased funding for dengue research and treatment programs in regions heavily affected by the disease, such as the Philippines and Thailand, contribute to the growth of this segment.

Buruli ulcer treatment is the fastest-growing segment in the neglected tropical disease treatment market in 2024, driven by increased disease prevalence, advancements in therapeutic options, and enhanced global awareness. In 2024, 1,861 suspected cases were reported across 10 countries, with 1,497 cases in the African Region and 364 in the Western Pacific Region. This growth is attributed to rising case numbers, particularly in Africa and Oceania, and the development of more effective antibiotic regimens and surgical interventions. For instance, in 2024, the World Health Organization reported over 25,000 new cases annually across more than 30 countries, underscoring the need for improved treatment strategies. Additionally, international initiatives like the Kigali Declaration have mobilized substantial resources to combat neglected tropical diseases, including Buruli ulcer.

Product Insights

Drugs remain the largest revenue-generating segment in the neglected tropical disease treatment market of 69.14% in 2024, primarily due to their critical role in managing prevalent parasitic infections such as leishmaniasis, schistosomiasis, and onchocerciasis. These diseases are endemic in tropical regions, necessitating effective pharmaceutical interventions. The World Health Organization's Global Report on Neglected Tropical Diseases 2024 underscores that, despite significant progress, the path to achieving the 2030 targets necessitates continued and enhanced efforts in drug development, distribution, and access. Furthermore, a partnership between Bayer and Fiocruz in 2023 aimed to strengthen the supply of Nifurtimox to Brazil, demonstrating collaborative efforts to enhance treatment accessibility.

Vaccine by Product in the Neglected Tropical Disease Treatment Market is the fastest-growing segment in 2024. Key drivers include increased government initiatives, rising awareness, and advancements in vaccine development. For instance, the WHO prequalified the R21/Matrix-M malaria vaccine in December 2023, leading to its launch in Ivory Coast in July 2024, the initial rollout targeted approximately 250,000 children aged 0 to 23 months across 38 districts, with plans to expand further. The Serum Institute of India plans to produce up to 100 million doses annually, offering the vaccine at under USD 4 per dose. Additionally, Bharat Biotech's oral cholera vaccine, Hillchol, received approval from India's drug regulator in August 2024, addressing global vaccine shortages. These developments underscore the growing emphasis on vaccines in combating neglected tropical diseases.

Regional Insights

The North American neglected tropical disease (NTD) treatment market is projected to hold a significant share in 2024, driven primarily by the region's advanced healthcare infrastructure, strong research and development activities, and the involvement of multinational pharmaceutical companies. While the prevalence of NTDs is relatively low in North America compared to regions like Africa, Asia, and Latin America, the region plays a crucial role in the global fight against these diseases through research, policy-making, and financial support. The key drivers for the market include increased awareness about NTDs, particularly in the context of global health initiatives and public health policies that emphasize equity in healthcare access. Government agencies, such as the U.S. Department of Health and Human Services, and non-governmental organizations (NGOs) are investing heavily in addressing the global burden of NTDs, with a particular focus on treatments for diseases like leishmaniasis, trachoma, and lymphatic filariasis.

Additionally, the fast pace of research and innovation in the pharmaceutical industry has led to the creation of more targeted and affordable treatments, with an increasing focus on making these therapies more accessible to affected populations. Market trends include a strong emphasis on R&D, public-private partnerships, and a growing push for inexpensive drug solutions that can be scaled globally to address the needs of both high-income and low-income regions.

U.S. Neglected Tropical Disease Treatment Market Trends

The U.S. neglected tropical disease treatment market is expected to see significant advancements driven by increased government funding, growing awareness, and regulatory progress. The U.S. government has made substantial commitments to combat NTDs, both domestically and globally, with agencies like the U.S. Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) funding research programs aimed at better understanding these diseases and developing innovative treatments. Additionally, the U.S. Food and Drug Administration (FDA) has approved a range of new treatments targeting diseases such as Chagas disease, leishmaniasis, and onchocerciasis, signaling continued regulatory support for NTD therapies. For instance, in Apr 2024, PaxMedica achieved a significant milestone by completing three pivotal registration/validation batches of PAX 101, an intravenous formulation of suramin. This advancement paved the way for a New Drug Application (NDA) submission to the FDA, aiming to provide the first and only form of suramin for treating Stage 1 Human African Trypanosomiasis (HAT), a fatal neglected tropical disease caused by Trypanosoma brucei rhodesiense.

Pharmaceutical companies in the U.S. are increasingly engaging in the development of new therapies for NTDs, driven by financial incentives, research breakthroughs, and international collaborations aimed at tackling neglected diseases. For instance, in Oct 2024, the U.S. Agency for International Development (USAID) allocated approximately USD 115 million for neglected tropical disease (NTD) programs. This funding supports integrated NTD control efforts in 26 countries, aiming to eliminate or control diseases such as lymphatic filariasis, onchocerciasis, and schistosomiasis. Furthermore, partnerships between U.S. pharmaceutical companies and global health organizations are becoming more common, enhancing efforts to distribute these treatments to affected populations in low-resource settings. These developments are positioning the U.S. as a key player in the global NTD treatment market, focusing on both the advancement of medical treatments and the accessibility of these solutions in underserved regions..

Europe Neglected Tropical Disease Treatment Market Trends

The European market for neglected tropical disease (NTD) treatment is heavily influenced by collaborative research and development initiatives. In May 2023, the European Union launched a USD 140 million research initiative through the Horizon Europe program, focusing on innovative treatments for diseases such as leishmaniasis, schistosomiasis, and lymphatic filariasis. This initiative is part of Europe’s broader commitment to advancing medical solutions for neglected diseases that disproportionately affect low-income countries. In addition to funding new drug research, the program also supports the development of vaccines and improved diagnostic methods. These collaborative efforts often involve partnerships between pharmaceutical companies, academic institutions, and international health organizations, driving substantial progress in NTD research.

In October 2022, the EU-funded project “Chagas Disease Diagnostics” developed a rapid diagnostic test for Chagas disease, improving early detection and facilitating more effective treatments. This is an example of how Europe is enhancing diagnostic capabilities, which are crucial in preventing the progression of NTDs in endemic regions. With the region’s emphasis on diagnostic innovation, the European market for NTD treatments is poised to grow as novel detection methods allow for quicker interventions and more targeted treatments. These advancements also contribute to Europe’s broader public health goals, aligning with global health security efforts to reduce the burden of NTDs worldwide.

UK neglected tropical disease treatment market in global efforts to combat neglected tropical diseases, particularly through strategic funding and research initiatives. The UK has been actively involved in supporting NTD initiatives, including the USD 256 million Accelerating Sustainable Control and Elimination of Neglected Tropical Diseases (ASCEND) programme, prioritizing diseases like river blindness and lymphatic filariasis. The government’s funding is directed towards both the development of new treatments and the distribution of existing ones to affected regions.

In addition to these funding commitments, the UK has recognized the growing risk posed by climate change on the spread of NTDs. A report released in January 2023 highlighted how warmer temperatures and changing rainfall patterns are expanding the habitats of mosquitoes and other vectors that transmit diseases like dengue and Zika virus. As a result, the UK government has prioritized research into climate-driven shifts in NTD patterns, especially in Europe. The country has also supported global initiatives focused on vector control, aiming to mitigate these emerging threats. This proactive approach positions the UK as a leader in addressing the intersection of climate change and neglected tropical diseases.

Germany neglected tropical disease market, focusing on innovative diagnostics and treatments. The country excels in developing molecular diagnostic tools and point-of-care technologies, enhancing early detection and treatment for diseases like schistosomiasis and leishmaniasis. Germany’s strong pharmaceutical industry collaborates with global health organizations to improve access to treatments, while its participation in international initiatives strengthens health systems and aids in the elimination of diseases such as onchocerciasis.

France neglected tropical disease market is a leader in vaccine development and international collaboration to combat neglected tropical diseases (NTDs). With companies like Sanofi Pasteur at the forefront, France has developed vaccines for diseases such as dengue and leishmaniasis, contributing to global efforts to reduce the incidence of these diseases in endemic areas. The French government has also invested in global partnerships with organizations like the WHO and Médecins Sans Frontières (MSF) to improve access to treatment and strengthen healthcare systems in regions burdened by NTDs. France’s efforts to promote vaccine development, alongside its support for international health initiatives, are central to the global fight against neglected tropical diseases.

Asia Pacific Neglected Tropical Disease Treatment Market Trends

The Asia Pacific (APAC) region is experiencing significant growth in the neglected tropical disease (NTD) treatment market, driven by increasing healthcare investments and government initiatives aimed at addressing the high burden of these diseases. The region faces a substantial challenge with diseases like schistosomiasis, lymphatic filariasis, and onchocerciasis, which are prevalent in both rural and underserved areas. To combat these diseases, many APAC countries are implementing mass drug administration (MDA) campaigns, which have been effective in reducing transmission and improving public health outcomes. These government-led efforts, combined with rising awareness and funding, are contributing to the region’s growing focus on NTDs. For instance, A notable initiative in the Asia-Pacific (APAC) region is the mass drug administration (MDA) campaign launched by Jharkhand, India, in 2024. This campaign aims to eliminate lymphatic filariasis (LF) by 2027, targeting approximately 12.7 million people across 80 blocks in nine districts, including Chatra, Godda, and Palamu. The program utilizes a combination of diethylcarbamazine (DEC), albendazole, and ivermectin, administered through both booth-based and door-to-door methods. Excluding children under two, pregnant women, and individuals with serious illnesses, the campaign emphasizes community involvement, engaging various departments such as education, sanitation, and local governance.

In addition to public health initiatives, the APAC region is also seeing advancements in diagnostic technologies. The adoption of molecular diagnostics and point-of-care testing is enhancing early detection and ensuring timely treatment in remote areas. These technologies are critical for managing NTDs in regions with limited healthcare infrastructure. Public-private partnerships are also playing a crucial role by facilitating the development and distribution of essential treatments and vaccines. These collaborations are ensuring that medicines reach vulnerable populations, driving progress in the fight against NTDs across the region and making healthcare solutions more accessible to those most in need.

Japan's neglected tropical disease (NTD) treatment market is expanding due to the country’s active involvement in global health initiatives and ongoing advancements in medical research. The market is growing steadily as Japan continues to invest in the development of new therapies and supports global NTD elimination programs. This growth is further driven by the country’s focus on enhancing healthcare infrastructure and its strategic partnerships with international organizations. In addition, Japan's commitment to addressing climate change-related health risks is influencing the market. As warmer temperatures and changing weather patterns affect the spread of vector-borne diseases such as malaria and dengue, Japan is prioritizing research into these shifts. This focus on climate-driven NTD trends is expected to further stimulate demand for treatment solutions in the country.

China's neglected tropical disease (NTD) treatment market is growing steadily, supported by the country's large population and the increasing prevalence of diseases such as schistosomiasis, lymphatic filariasis, and leishmaniasis. The market's expansion is driven by China's ongoing public health initiatives, including the Healthy China 2030 plan, which focuses on improving healthcare access and addressing NTDs.

The government’s active involvement in international collaborations and funding for research on NTDs also plays a significant role in market growth. Additionally, China's efforts to modernize its healthcare infrastructure, especially in rural and underdeveloped areas, are facilitating the distribution of treatments to affected populations. The market is further bolstered by advancements in diagnostic technologies and the development of more effective therapies.

Latin America Neglected Tropical Disease Treatment Market Trends

The neglected tropical disease (NTD) treatment market in Latin America is experiencing steady growth, driven by the region's high burden of diseases such as Chagas disease, leishmaniasis, and dengue. The market is supported by regional health initiatives and government programs aimed at reducing the prevalence of these diseases through treatment and prevention strategies.

Key factors contributing to market growth include increased investments in healthcare infrastructure and ongoing research into more effective treatments. Latin American countries are also benefiting from international collaborations, such as those with the World Health Organization (WHO), which focus on vector control and disease elimination programs. The increasing availability of affordable treatments and vaccines in the region is another driver for the market's growth.

Brazil's neglected tropical disease (NTD) treatment market is expanding due to the country’s high disease burden, particularly with diseases like Chagas disease, malaria, and leishmaniasis. The Brazilian government has been proactive in addressing these issues through national health programs aimed at improving treatment access and reducing the prevalence of NTDs. The market is supported by Brazil’s participation in international collaborations and funding from organizations such as the Global Fund and the Bill & Melinda Gates Foundation. Brazil is also investing in the development of new treatments and vaccines, which is further driving market growth. However, challenges such as the need for more widespread genetic screening and logistical barriers in rural areas continue to impact treatment distribution.

Middle East & Africa Neglected Tropical Disease Treatment Market Trends

The neglected tropical disease (NTD) treatment market in the Middle East and Africa (MEA) is growing due to the high prevalence of diseases such as leishmaniasis, schistosomiasis, and lymphatic filariasis in the region. Despite challenges such as underfunded healthcare systems and inadequate disease surveillance, government and international organizations are working to improve access to treatments and eliminate these diseases. The market growth is supported by increasing government funding, international collaboration, and advancements in research, particularly in the development of new treatments and diagnostic tools. Countries in the MEA region are also benefiting from global initiatives focusing on vector control and the distribution of medicines to endemic areas. However, ongoing logistical challenges and limited healthcare infrastructure in certain regions continue to slow the market's potential.

Saudi Arabia's neglected tropical disease (NTD) treatment market is expanding steadily, driven by the country's efforts to improve healthcare access and prevent diseases. While the prevalence of NTDs like leishmaniasis remains relatively low compared to other regions, Saudi Arabia has made notable progress in tackling these diseases through both local initiatives and global collaborations. The market benefits from government programs focused on strengthening healthcare infrastructure and providing treatment in rural and border areas. Furthermore, Saudi Arabia is investing in NTD research and partnering with international organizations to boost its disease control efforts. The country's robust healthcare system and commitment to health research are key drivers behind the growth of the NTD treatment market.

Key Neglected Tropical Disease Treatments Company Insights

The neglected tropical disease (NTD) treatment market is characterized by significant contributions from major pharmaceutical companies. F. Hoffmann-La Roche, Bayer, GlaxoSmithKline, Novartis, Pfizer, Eisai, Sanofi, Astellas Pharma, Takeda, and Gilead Sciences are all involved in research and development aimed at addressing various NTDs. These companies are focusing on developing treatments and vaccines for diseases such as malaria, Chagas, leishmaniasis, dengue, and sleeping sickness. Partnerships with organizations like the World Health Organization and other global research entities are common in their efforts to improve access to treatment in low-income regions. These companies also aim to expand the availability of affordable medications and vaccines, ensuring broader access in endemic areas. The market is influenced by both ongoing collaborations and continued investment in NTD-related research.

Recent Developments

• In July 2025, Novartis and Medicines for Malaria Venture received approval in Switzerland for Coartem Baby, the first malaria treatment specifically designed for newborns and infants under 11 pounds. This approval addresses a significant gap in malaria treatment, particularly in regions with high malaria prevalence, such as sub-Saharan Africa and Southeast Asia.

• In August 2024, researchers at the University of York developed a new approach to tackling leishmaniasis, a major NTD affecting millions worldwide. This breakthrough includes both a new vaccine and a novel drug designed to prevent and treat leishmaniasis more effectively. The research, supported by several global health organizations, could significantly reduce the burden of this disease in tropical regions and improve patient outcomes by providing a more affordable and accessible treatment option.

• In May 2024, the World Health Organization (WHO) and the Global Health Innovative Technology Fund formalized a partnership to enhance access to affordable, effective drugs, vaccines, and diagnostic tools for neglected tropical diseases. This collaboration aims to expedite the development and distribution of key NTD treatments in low-income and remote regions.

Neglected Tropical Disease Treatment Market